Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 5,325 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Vitamin D Deficiency
Interventions: cholecalciferol; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 69 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Muscular Atrophy (SMA)
Interventions: RO7204239, Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
Interventions: Duvelisib, Docetaxel; Drug
Lead sponsor: Kartik Sehgal, MD; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: 5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 8
States / cities: Bakersfield, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 11
States / cities: Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more

Conditions: ALK Positive Malignancies
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Loma Linda, California • Aurora, Colorado + 2 more

Conditions: Collapse of Thoracic Vertebra, Collapse of Lumbar Vertebrae
Interventions: Dexmedetomidine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: HIV Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 28
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Adverse Pregnancy Outcome
Interventions: Lovenox 40mg; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Atopic Dermatitis
Interventions: Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small Cell Lung Carcinoma
Interventions: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: New Haven, Connecticut • Las Vegas, Nevada • New York, New York + 1 more

Conditions: Menopausal Women, Insomnia
Interventions: Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant; Behavioral · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Boston, Massachusetts • Novi, Michigan • Winston-Salem, North Carolina + 2 more

Conditions: Hematologic Neoplasm, Neoplasms, Hematologic Malignancies
Interventions: CC-486; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: Gainesville, Florida • Baltimore, Maryland • Houston, Texas

Conditions: HIV Infections
Interventions: Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 5
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
Interventions: CX-01, Azacitidine, Bone marrow biopsy, Peripheral blood draw; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Leuprolide acetate, Apalutamide, Radical prostatectomy; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tetrology of Fallot, Heart Ventricle, Hypoplastic Left Heart
Interventions: Dexmedetomidine; Drug
Lead sponsor: Athena Zuppa; Other
Eligibility: 1 Hour to 30 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Postoperative, Premature Infant, Opioid Use
Interventions: Acetaminophen, Saline; Drug
Lead sponsor: St. Louis University; Other
Eligibility: Up to 1 Month
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Pain
Interventions: Ketamine; Drug
Lead sponsor: Theresa Lii; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence, Urinary Incontinence
Interventions: Estradiol 0.01% Vag Cream, Placebo vaginal cream; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Gastrointestinal Cancer
Interventions: Proton therapy; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COVID-19
Interventions: Discontinuation of ARB/ACEI, Continuation of ARB/ACEI; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Small Cell Lung Cancer
Interventions: SC-002; Drug
Lead sponsor: Stemcentrx; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 1 more

Conditions: Myelodysplastic Syndrome
Interventions: Entinostat, Pembrolizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 19
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 13 more

Search by objective public record fields.

The Effect of a Meal on Vitamin D Absorption

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Study of Dexmedetomidine in Spine Surgery

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer

Understanding Dexmedetomidine in Neonates After Open Heart Surgery

Postoperative Pain Control & Relief in Neonates

Observational Study of Ketamine Infusions for the Treatment of Chronic Pain

Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery

Proton Radiotherapy for Upper Gastrointestinal Malignancies

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents